Company intelligence / Profile preview
Esperance Pharmaceuticals, Inc.
Houston, Texas, United Statesesperancepharma.com ↗
- Ownership
- Private
- Employees
- ~11
- Development stage
- Other
01
Overview
EP-100 completed Phase 1 clinical trials and advanced to Phase 2 clinical trials in ovarian cancer. The Phase 2 trial was a randomized, multi-center study of EP-100 in combination with paclitaxel for advanced ovarian cancer[7].
- Therapeutic areas
- OncologyHematology
- Modalities
- Peptide conjugatesTargeted membrane-disrupting peptides (tMDPs)Antibody-drug conjugates
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
MD Anderson Cancer CenterSanofi
Beyond the preview
Go deeper on Esperance Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Esperance Pharmaceuticals, Inc..